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Abstract
Background: Tuberculosis (TB) is the leading cause of mortality among infectious diseases worldwide. Ninty five
percent of TB cases and 98% of deaths due to TB occur in developing countries. Globally, the mortality rate has
declined with the introduction of effective anti TB chemotherapy. Nevertheless, some patients with active TB
still die while on treatment for their disease. In Ethiopia, little is known on survival and risk factors for mortality
among a cohort of TB patients. The objective of the study is to determine the magnitude and identify risk
factors associated with time to death among TB patients treated under DOTS programme in Addis Ababa,
Ethiopia.
Methods: This is a retrospective cohort study. Data was obtained by assessing medical records of TB patients
registered from June 2004 to July 2009 G.C and treated under the DOTS strategy in three randomly selected health
centers. A step-wise multivariable Cox’s regression model and Kaplan- Meier curves were used to model the
outcome of interest. Mortality was used as an outcome measure. Person-years of observation (PYO) were calculated
from the date of starting anti-TB treatment to date of outcome and was calculated as the number of deaths/100
PYO. Statistical analysis SPSS version 16 was used for data analysis and results were reported significant whenever
P-value was less than 5%.
Results: From a total of 6,450 registered TB patients 236(3.7%) were died. More than 75% death occurred within
eight month of treatment initiation. The mean and median times of survival starting from the date of treatment
initiation were 7.2 and 7.9 months, respectively. Comparison of survival curves using Kaplan Meier curves
method with log-rank test showed that the survival status was significantly different between patient categories
as well as across treatment centers (P < 0.05). The death rate of pulmonary positive, pulmonary negative and
extra pulmonary TB patients were 2.7%, 3.6%, and 4.3%, respectively. Body weight at initiation of anti-TB
treatment (<35 kg), patient category, year of enrollment and treatment center were independent predictors for
time to death.
Conclusions: Most of the patients were died at the end of treatment period. This underlines the need for devising
a mechanism of standardizing the existing DOTS programme and nutritional support for underweight patients for
better clinical and treatment outcome.
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In 2008, there were an estimated 8.9-9.9 million incident
cases of TB, 9.6-13.3 million prevalent cases of TB, an
estimated 1.3 million (range, 1.1-1.7 million) deaths,
including 0.5 million (range, 0.45-0.62 million) deaths
among women, occurred among HIV-negative incident
cases of TB, and there were an estimated 0.5 million
deaths among incident TB cases who were HIV-positive
[1]. In 2005, 15.4 million TB cases were reported globally,
among 8.8 million people new TB cases, 3.9 million were
smear positive, and 1.7 million people died of TB in the
same year [2]. Ninety eight percent of TB deaths occur in
the developing countries and if left unchecked, with in
20 years, TB will kill about 35 million people [2]. WHO
developed the DOTS strategy as the internationally
recommended approach to TB control in the mid-1990s.
DOTS is also the foundation of the Stop TB Strategy,
which was launched by WHO in 2006 to guide TB con-
trol efforts during the period 2006-2015. The start of
WHO efforts to systematically monitor progress in TB
control on an annual basis in 1995 coincided with global
promotion and expansion of the DOTS strategy [1].
In Ethiopia, TB has long been recognized as a major
public health problem since the 1950s [3] and the coun-
try has been implementing the WHO recommended
DOTS (Directly Observed Treatment Short-course)
strategy since 1992[4]. At present, TB control strategy
in Ethiopia relies on WHO recommended Stop TB
Strategy and it has been implemented in the country
since 2006[5].According to the 2008 WHO TB report
[4], Ethiopia ranks 7th in the list of the world’s2 2h i g h
burden countries for TB with incidence estimated at
379/100,000 for all forms of TB and 168/100,000 for
smear positive TB. According to the Ministry of Health
hospital statistics data, TB mortality rate is estimated at
84 per 100,000 populations per year [3].
TB mortality has been variously attributed to a dra-
matic rise in drug resistance [6] and to deteriorations in
TB services [7,8] and the risk of dying could be reduced
through improved care [9,10]. So to avert the problem
of TB mortality, policy makers should devise a plan,
with clear reflection on the magnitude of mortality and
associated risks factors of TB, to improve the quality
and standard of TB care. The objective of this paper
was to identify the magnitude and risk factors associated
with death among a cohort of TB patients treated under
DOTS programme in Addis Ababa, Ethiopia.
Methods
Study setting
This institution based retrospective study was carried
out in three randomly selected health centers of Addis
Ababa, the capital city of Ethiopia. Addis Ababa has a
surface area of 540 Square kilometer. In the year 2007
the population of the city was about 2.74 million, 5046
people live per Square kilometer, and 52.4% of the resi-
dents were females [11]. Administratively, the city is
divided into 10 sub-cities which are in turn divided into
99 lowest administrative units known as Kebeles. The
health institutions in the city comprise of 5 district hos-
pitals and 1 specialized hospital which are all adminis-
tered by the Federal Ministry of Health (MOH), 5
hospitals administered by other Governmental Agencies
and 30 private owned hospitals. Moreover, the city has
24 health centers run by the government. Similarly, in
the private sector there are 109 special clinics, 169
higher clinics and 146 medium clinics. The Addis
Ababa city administrations had potential health service
coverage of 21% in 2009 G.C [12].
Study design and participants
Health institution-based retrospective cohort study was
conducted in Addis Ababa from February 2010 to
March 2010 G.C to evaluate treatment outcome among
TB patients. Information for this study was extracted
from documents of all TB cases registered from June
2004 to July 2009 G.C in three DOTS clinic located in
three randomly selected health centers. The three health
centers constitute different health service coverage areas
of the city. In order to attain representativeness of dif-
ferent health service coverage the sub cities were cate-
gorized by their health service coverage in to low,
medium, and high health service coverage (Table 1) and
the available health centers were listed in each group.
From each health service coverage group one health
center was randomly selected, namely, Teklehaymanot
Health Center from high health service coverage, Selam
Health Center from medium health service coverage,
and Kolfe Heath Center from low health service
converge.
Table 1 Health service coverage of Addis Ababa by sub
cities, 2009
Sub cities Health Service Coverage in% Remark*
Kolfe 16 Low
Nifas silk-Lafto 22 Low
Yeka 33 Low
Adisketema 35 Medium
Gullele 35 Medium
Bole 40 Medium
Arada 50 Medium
Kirkos 50 Medium
Akaki 60 High
Lideta 66 High
Addis Ababa 34.7
Source: Addis Ababa City Administrative Health Bureau.
*Working definition to enable us to stratify the sub cities.
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Type of TB
According to the standard definitions of the Ethiopian
National Tuberculosis and Leprosy control Program
guideline (NLCP)[5], type of TB was defined as (a) pul-
monary TB, smear-positive (a patient with at least two
sputum specimens which were positive for acid-fast
bacilli (AFB) by microscopy, or a patient with only one
sputum specimen which was positive for AFB by micro-
scopy, and chest radiographic abnormalities consistent
with active pulmonary TB), (b) pulmonary TB, smear-
negative (a patient with symptoms suggestive of TB,
with at least two sputum specimens which were negative
for AFB by microscopy, and with chest radiographic
abnormalities consistent with active pulmonary TB
(including interstitial or miliary abnormal images), or a
patient with two sets of at least two sputum specimens
taken at least two weeks apart, and which were negative
for AFB by microscopy, and radiographic abnormalities
consistent with pulmonary TB and lack of clinical
response to one week of broad spectrum antibiotic ther-
apy) and (c) Extra pulmonary TB (EPTB) (this included
tuberculosis of organs other than the lungs, such as
lymph nodes, abdomen, genitourinary tract, skin, joints
and bones, meninges, etc) [Figure 1].
Patient category
At entry to DOTS patients were categorized according
to the Ethiopian NLCP national guideline (a) as new
cases (patient who has never had treatment for TB
before or has been on anti- TB treatment for less than
four weeks ), (b) relapse (a patient who has been
declared cure or treatment completed of any form of
TB in the past but who reports back to the health ser-
vice and is found to be AFB smear positive or culture
positive), (c) treatment failure (a patient who, while on
treatment remained smear- positive or become again
smear-positive at the end of the five month or later
after commencing treatment), (d) returned after default
(a patient who had previously been recorded as
defaulted from treatment and returns to the health facil-
ity and found to be smear positive sputum), (e) transfer
in (a patient who started treatment in one health facility
and transferred to another health facility to continue
treatment), and (f) Other (a patient who does not fit in
any of the above mentioned categories)
Treatment Outcome
this variable was recorded as (a) cured (finished treat-
ment with negative bacteriology result at the end of
treatment), (b) treatment completed (patient finished
treatment but no bacteriology result at the end of the
treatment), (c) treatment failure (smear positive at five
months despite correct intake of medication), defaulter
(patients who interrupted their treatment for two conse-
cutive months or more after registration), died (patients
who died from any cause during the course of treat-
ment), (d) transferred out (patients whose treatment
results are unknown due to transfer to another health
facility) and (e) successfully treated (the sum of patients
who are declared “cured” and those who have “com-
pleted” treatment). Survival time was defined as the
time in days from the beginning of treatment to death
from tuberculosis as the main or associated cause. Cen-
soring occurred either at the end of the study or due to
death from other causes and include defaulters and
transfer outs.
Definition for health service coverage
Low health service coverage: when the health service
coverage is less than 33% for the sub city population.
Medium health service coverage: when the health
service coverage is between 35-50% for the sub city
population.
High health service coverage: when the health ser-
vice coverage is greater than 50% for the sub city
population.
Data collection procedures
The registration documents of each heath centers con-
tain basic information such as patient’s age, sex, address,
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Figure 1 Diagnostic algorithms for pulmonary TB and extra
pulmonary TB (Adapted from the Federal Ministry of Health of
Ethiopia (FMOH): Tuberculosis, Leprosy and TB/HIV Prevention
and Control Programme Manual. Addis Ababa: MOH 4th edition.
2008).
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at base line, 2
nd,5
th and 7
th month, treatment regimen,
treatment started date, treatment stopped date and
treatment outcome (as defined above). Data were col-
lected by structured data sheet from the selected health
centers registration book. Data were extracted from the
registration book by health professionals (nurse/health
officer) working in TB clinic after attending one day
orientation on the structured data sheet by the principal
investigator. To ensure quality of the collected data the
following measures were taken: (a) A one day training
was given for data collectors before the start of data col-
lection, (b) he overall activities of data extraction were
monitored by the principal investigator, and there was
strict supervision during data collection, (c) all com-
pleted data sheets were examined for completeness dur-
ing data collection, (d) consistencies of the collected
data were checked during analysis.
Analysis variables
The independent variables considered for the analysis
were age, sex, type of TB, patient category (new, relapse,
failed, return after default, transfer in, and other); AFB
smear result and treatment start and stopped date. The
dependent (outcome) variable was time to death of a
patient which was ascertained by calculating the differ-
ence between the date of initiation of anti-TB treatment
and date of outcome. The difference was divided by 30
to determine time to an event in month.
Ethical consideration
Before reviewing patient documents ethical clearance
was obtained from Aklilu Lemma Institute of Pathobiol-
ogy, Addis Ababa University (ALIPB AAU), Addis
Ababa City Administrative Health Bureau and health
offices of the three randomly selected sub-cities’. Official
letter of co-operation from health offices of the three
sub-cities were written to respective health facilities. In
order to ensure confidentiality of the information,
names or identification number of study participants
were not included in the data sheet.
Statistical analyses
The quantitative data extracted from the registration
book were checked for completeness and consistency by
the principal investigator. Data entry and analyses were
carried out using SPSS version 16. Descriptive statistical
methods were used to summarize the socio-demographic
characteristics of the study participants. Kaplan-Meier
method with log rank test were used to estimate survival
probability and compare survival curve for pulmonary
positive, pulmonary negative and extra pulmonary TB
patients. Cox’s proportional hazards model was used to
identify risk factors for time to death within treatment
period using forward stepwise procedure. Variables
showing significant association (P < 0.05) in the bivariate
analysis were included in the multivariable Cox’s propor-
tional hazards model. Adjusted hazard ratio (AHR) and
corresponding 95% confidence interval (95%CI) were esti-
mated for potential risk factors included in the multivari-
able model. Mortality was used as an outcome measure.
Person-years of observation (PYO) were calculated from
the date of starting anti-TB treatment to date of outcome
if the patient was alive, or to date of death. The study out-
comes of participants were censored if they were reported
to be dead at the time of data collection. Mortality was
calculated as the number of deaths/100 PYO.
Results
Demographic characteristics
In this retrospective document analysis, socio-demo-
graphic and medical information of 6,450 registered
TB patients was summarized. The mean, standard
deviation and median age of the study participants
were 30.13, 13.7 and 28.0 years, respectively. Out of
the total study participants 46.8% were males and
77.9% were in the age group of 15-44 years. The study
participates constitute were 46.5% from Teklehaymanot
heath center, 16.7% from Selam heath center and
36.7% from Kolfe health centers. In total, 25.6% were
pulmonary positives, 33.9% were pulmonary negatives
and 40.5% were extra pulmonary TB patients. Majority
of the study participants (88.9%) were new cases
(Table 2).
Survival analysis of TB patients
Of the 6,450 registered patients, 6198(96.3%) survived
the entire follow-up period. Time until an event (death,
lost to follow up, transcestion due to treatment comple-
tion) for Person-years follow-up was 3753.67. The gen-
eral mortality rate per 100 PYO was 6.3/100(6.3%) per
annum for the cohort. The trend of TB mortality is
being gradually showing decreasing in pattern as dis-
played in Figure 2. As depicted in Figure 3, more than
75% death occurred within eight month of treatment
initiation. In this study, the proportion of death from
pulmonary positives, pulmonary negatives and extra pul-
monary TB patients were 2.7%, 3.6%, and 4.3%, respec-
tively. Patient age, weight at initiation of anti-TB
treatment, patient category, year of enrollment and
treatment center were significantly associated with time
to death (p < 0.05). TB patients weighting more than
34 kg at initiation of anti-TB treatment were 11.5% less
likely to die [AHR = 0.899 with 95%CI of 0.804 to
0.973] compared with those weighting less than 34 kg.
TB patients treated in Selam HC were 1.5 times [AHR
= 1.498 CI at 95% (1.389- 1.616)] more likely to die
compared to those treated in Teklehaimont HC.
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significantly higher during 1997-1998 [AHR = 1.175 CI
at 95% (1.047-1.320)], 1998-1999 [AHR = 1.207 CI at
95% (1.075-1.355), 2000-2001 [AHR = 1.137 CI at 95%
(1.012-1.278)]. Moreover retreated TB patients were
1.74 times [AHR = 1.74 CI at 95% (1.439-2.096)] more
likely to die compared to new Tb patients (Table 3).
Discussion
WHO defines TB mortality as the number of TB cases
dying during treatment, regardless of the cause [13].
The mortality in our study was higher than in china
[14] but lower than in those reported in previous studies
including 24% in Baltimore City, USA [15], 14% in Vaud
County, Switzerland [16] and similar to the mortality
found in Addis (4%) and to the National (3%) [12]. The
Mean and median duration from the onset of treatment
to death in the current study were similar to a study
conducted in south India, where by 94-97% of patients
were surviving at the end of seven months of anti-TB
treatment, irrespective of TB categories [17]. A study
conducted in Chennai city [18] showed less survival rate
(91%) compared to our study. This difference may be
due to long follow up period in Chennai study and dif-
ferent number of study subjects. In other studies, 6% of
the 676 patients died during the course of treatment; all
patients who died had pulmonary TB [19]. Of the 39
patients who died, 65.0% died within 2 months of the
start of treatment [19] and in other study, the survival
probabilities were 97.5%, after the first month of treat-
ment, 96% after the 3 months, 95% after 6 months and
93% after 1 year [20]. Unlike to our study, other studies
have also found that a significant proportion of patients
died in the early stages of treatment [21,22]. Early mor-
tality reflects advanced disease and could be attributed
to delayed treatment and late diagnosis [22,23]. In Viet-
nam study, similar to our finding, among 27 deceased
patients the median time interval from treatment initia-
tion to death was 8 months (IQR 5 to 11 months) [24].
Other studies demonstrated high risk of death during
the first 2 months of anti-tuberculosis therapy [25-27].
Other study similar to our study showed the risk of
Figure 2 T r e n do fT Bm o r t a l i t ya c r o s st h eh e a l t hc e n t e ri n
Addis Ababa, March 2010.
Figure 3 Survival curve of pulmonary positive, pulmonary
negative and extra pulmonary registered TB patients in Addis
Ababa, Ethiopia, March 2010.
Table 2 Characteristics of study participants in Addis
Ababa, Ethiopia March 2010
Patient Characteristics Number (%)
Sex
Male 3017(46.77)
Female 3433(53.23)
Age categories
0-14 459(7.12)
15-24 1932(29.95)
25-34 2023(31.36)
35-44 1069(16.57)
45-54 537(8.32)
55-64 251(3.89)
>65 179(2.77)
Treatment center
Teklehaimanot HC 3002(46.54)
Selam HC 1078(16.71)
Kolfe HC 2370(36.75)
TB patients Category
New 5736(88.93)
Relapse 160(2.48)
Failure 13(0.20)
Default 12(0.19)
Transfer in 164(2.54)
Others 365(5.66)
Type of TB
Pul.postive 1652 (26.5)
Pul.negative 2187(33.9
Extra pulmonary 2611(40.5)
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from the second six months to the final eight months;
hence it is likely that these deaths were due to drug sen-
sitive or drug-resistant relapse [18].
In our study, general mortality rate per 100 PYO was
6.3/100(6.3%) per annum for the cohort which is similar
to other studies. The general mortality rate for rural
south India cohort was 61.0/1000 person-years or 6.1%
per annum[28], which was not different from the mor-
tality rate of 6% per annum reported for the Chennai
urban cohort for the year 2000[18] but higher than a
study in southern Ethiopia which shows mortality per
100 PYO was 2.5% per annum [29].
In our study baseline body weight was significantly
associated with higher death. Similar finding was
observed in south India, in which body weight at initia-
tion of anti-TB treatment (<35 kgs) was a significant
risk factors of death during anti-tuberculosis treatment
period [17,19]. Other study also reported that among
persons who were underweight at diagnosis, weight gain
of 5% or less after two months of treatment was asso-
ciated with an increased risk of relapse [30]. Similarly,
low BMI was significant risk factor for mortality in
patients with miliary tuberculosis (MTB) and lower BMI
was found in patients who were died [31]. It may be
assumed that malnutrition would be a clinical finding
reflecting the severity of pulmonary TB (PTB) and that
the determinant of in-hospital mortality would be due
to PTB severity rather than malnutrition itself [32].
Underweight was associated with a 10-fold increase in
TB mortality [33].
In our study treatment category was associated with
higher death particularly previously treated patients. The
characteristics of the TB patients associated with mor-
tality during anti-TB treatment was being in retreatment
case [34].Previously reported risk factors of mortality
among tuberculosis patients include advanced human
immunodeficiency virus (HIV) infection [35,36], multi-
drug resistance [36-38], and irregular treatment [39].
Similarly, multidrug resistance may explain the high
combined failure and death rate of 55% among patients
with transfer-out [24]. But in one study the mortality
amongst the patients with previously treated TB was not
statistically different [40]. This might be due to drug
resistance cases at hospital level whereby most patients
transferred or associated immune suppression at the
beginning of the treatment and HIV prevalence may
therefore be higher among patients in retreatment cases
compared to patients with reported treatment success
or these patients may not recover during treatment and
m a yb et r a n s f e r r e dw i t h o u tw ell established referral
system.
Our study is not without limitations. The data were
extracted from medical records of those already visited
and registered at the respective health facilities; it may
be subjected to selection bias. In many tuberculosis
patients, multiple causes of death may act simulta-
neously, so the cause of death may not be determined
accurately [41,42]. In Norway this misclassification was
shown to be considerable [43]. In the present study, the
analyses included all deaths, irrespective of the cause of
death, so misclassification of the cause of death might
Table 3 Results from multivariable Cox’s proportional hazard model of risk factors for death the during treatment
period, Addis Ababa, Ethiopia, March 2010
Variables Death status of the registered
TB patients
Adjusted Hazard Ratio
(AHR) (95% CI)
P-value
alive (n; %) died (n; %)
Treatment center 0.000
Teklehaimont HC 2919(99.5) 16(0.5) 1.00
Selam HC 947(95.8) 42(4.2) 1.50(1.40-1.60)
Kolfe HC 2170(92.4) 178(7.6) 1.05(1.00-1.12)
Year of treatment 0.001
July 2004 - June 2005 403(96.0) 17(4.0) 1.00
July 2005 - June 2006 1388(96.8) 46(3.2) 1.18(1.05-1.32)
July 2006 - June 2007 1520(95.8) 66(4.2) 1.21(1.078-1.36)
July 2007 - June 2008 1341(96.0) 56(4.0) 1.06(0.95-1.19)
July 2008 - June 2009 1384(96.4) 51(3.6) 1.14(1.01-1.28)
Patients category 0.000
New 5373(96.4) 200(3.6) 1.00
Retreated 663(94.8) 36(5.2) 1.74(1.439-2.096)
Body weight at initial stage of treatment 0.012
weight < 34 kg 462(95.1) 24(4.9) 1.00
weight ≥ 35 kg 5447(96.5) 197(3.5) 0.89(0.80-0.97)
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ure of secondary data, some of the data are incomplete
to gather the necessary variables such as HIV infection,
patient’s compliance, use of Directed Observed Treat-
ment, use of ART, CPT and other prophylaxis, co-mor-
bidity, drug resistance pattern. It is possible that some
patients hidden their history of previous anti-tuberculo-
sis treatment at the time of diagnosis and were inappro-
priately classified under different category. Despite the
above limitations, this study was conducted at health
centers that represent different level of potential health
s e r v i c ec o v e r a g ei ns u b - c i t i e s ,w h i c hi nt u r nr e f l e c tt h e
TB patient under DOTS program at primary health care
level in Addis Ababa and inclusion of several sites for
comparison, and to get higher sample size to elucidate
on the matter.
Conclusion
Higher death rate was noted in patients with low base-
line weights and patients who are previously treated
cases. Additionally, the death rate was varied across year
of enrollment. Therefore, reinforcing the existing DOTS
program and nutritional support for underweight
patients for better clinical and treatment outcome.
Strengthen the recording system for completeness of the
registry which is a common problem in practice and
conducting further study with different design and area
is needed to assess the TB mortality situation.
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